Ono Entered into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs for Cancer
Shots:
- Adimab will receive an up front & R&D funding and is also eligible to receive success-based milestones on research, clinical development, and regulatory progress along with royalties based on net sales
- Under the terms of the agreement, Ono to get an exclusive option to globally develop, manufacture, and commercialize the candidates & will also be responsible for evaluating and developing the candidates at the pre-clinical and clinical stages
- Additionally, Adimab will lead the discovery of novel therapeutic Abs against multiple targets selected by Ono and generate bispecific Ab product candidates
Ref: PR Newswire | Image: Ono Pharmaceutical
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
